Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

NCT06941766 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Intermediate Trophoblastic Tumor

Interventions

DRUG: QL1706
DRUG: Chemotherapy

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]